<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325623</url>
  </required_header>
  <id_info>
    <org_study_id>Epilepsy (E)-36</org_study_id>
    <nct_id>NCT01325623</nct_id>
  </id_info>
  <brief_title>Seizure Detection and Automatic Magnet Mode Performance Study</brief_title>
  <acronym>E-36</acronym>
  <official_title>Seizure Detection and Automatic Magnet Mode Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model
      106 VNS Therapy System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, observational, unblinded, multi-site study designed to collect data on patients
      implanted with a Model 106 VNS Therapy System from baseline through an EMU stay of up to 5
      days. After the EMU stay, patients will continue follow-up for safety for approximately two
      years or until final regulatory approval of the product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Seizures Reported by Investigators and Triple Review</measure>
    <time_frame>Epilepsy Monitoring Unit Stay</time_frame>
    <description>Subjects were admitted to the EMU and underwent standard continuous data collection of vEEG and ECG for 3 to 5 days. If a seizure occurred during the EMU stay, clinical investigators annotated the start and stop times, the type of seizure, the presumed seizure onset location, and the lobe of origin as applicable.
Following the EMU data collection phase of the trial, the de-identified, continuous electronic records (per patient) from the EMU period were provided to an independent and blinded triple review panel. This panel evaluated the EEG data and annotated seizure onset, seizure offset, and a description of seizure type. In the absence of video, seizure types could only be specified as: partial (particular type not denoted), generalized (non-absence), absence, or partial with secondary generalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Sensitivity Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</measure>
    <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
    <description>Sensitivity is the total number of seizures detected divided by the total number of seizures during EMU stay.Data used to support sensitivity analyses included digital ECG/EEG files,corresponding M106 device downloads,and CRF data.Seizure and non-seizure EEG segments were provided to independent reviewers to confirm seizure occurrence and define EEG seizure onset times.Seizure onset times were then compared with observed M106 device detections at the detection threshold setting for AutoStim that the patient was randomized to(SDA 2;60%,SDA 4;40%,SDA 6;20%).Sensitivity is only reported if the heart rate surpassed the programmed detection threshold.Number of participants is total number of subjects who had seizures during the EMU stay.
An &quot;Ictal tachycardia Seizure&quot; is a seizure with Ictal Heart rate &gt;= 100 bpm &amp; at least 55% increase, or 35 bpm increase from baseline) Bootstrap confidence intervals using 3000 bootstrap samples. n=total number of seizures; N= number of participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modeled Sensitivity Based on Heart Rate Increase Associated With Seizures by SDA Setting Post-Processed Through Bench-top Device Simulant</measure>
    <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
    <description>Sensitivity is defined as the total number of seizures detected divided by the total number of seizures during the EMU stay. Data used to support sensitivity analyses included digital ECG/EEG files, corresponding M106 device downloads, and CRF data. Seizure onset times were compared with modeled M106 device detections at the least sensitive setting capable of detecting the seizure based on the corresponding change in heart rate. The participants' surface ECG data collected during the trial and passed through DMSDAT, a validated bench‐top simulant of the Automatic Stimulation feature, was used to produce modeled results for each threshold for AutoStim setting (1;70%, 2;60%, 3;50%, 4;40%, 5;30% and 6;20%). Number of participants is total number of subjects who experienced seizures during the EMU stay.
Bootstrap confidence intervals using 3000 bootstrap samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential False Positives Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</measure>
    <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
    <description>Potential false positive rate is defined as the sum across all patients of the total number of potential false positive detections divided by the sum across all patients of the appropriate monitoring time during the EMU stay. Data used to support the potential false positive rate analyses included digital ECG/EEG files retrieved from the EMU evaluation, corresponding M106 device downloads, and triple review results of EEG recordings.
The evaluated EMU monitoring time includes a daily 3 minutes stepping exercise during which patients stepped up and down on a step stool at a submaximal effort leve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of Cardiac R-Wave Detection</measure>
    <time_frame>At Implant, First Titration Visit, Day 1 EMU and 12 Months</time_frame>
    <description>Cardiac R‐wave detection was evaluated against concurrent ECG data (i.e. detailed R‐wave test) collected during implant, the first titration visit, at the beginning of the EMU stay, and at the 12 month visit. R‐R intervals were calculated using detected R‐waves from the Implantable Pulse Generator (IPG) and from a standard ECG monitor during a pre‐specified time interval. A time series 10 seconds was recorded using the IPG SyncPulse feature. Simultaneously, a corresponding time series over the same interval was recorded using a standard ECG monitor. The total number of beats accurately detected in the entire study population is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Latency Period: Analysis of Observed Latency for True Positive Detections by Randomized SDA Setting</measure>
    <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
    <description>Latency is defined as the time difference between SDA detection time and the annotated seizure onset time. The earliest SDA detection was considered for each seizure. Seizure onset times were compared with M106 device detections at the randomized SDA setting. Negative latencies indicate that the SDA detection preceded the seizure onset time. The median latency is presented for seizures which met the definition of ictal tachycardia as well as all seizure types and indicate the observed latency range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Factors and Usability of the AspireSR® VNS Therapy® System.</measure>
    <time_frame>At implant/recovery up to EMU Discharge (2 to 4 weeks)</time_frame>
    <description>Usability survey data were collected from all site personnel who used the handheld programmer to evaluate the usability of the AspireSR® VNS Therapy® System.The device usability survey contained 17 questions that measure usability on a five-point Likert scale ranging from &quot;Extremely Difficult&quot; (5) to &quot;Extremely Easy&quot; (1). Site personnel were asked to assess usability of the software features, instructions for use, training materials, and overall usability of the system at four different time points. The time points include implant/recovery and the end of EMU.
Usability was calculated as percentage of the users who found the usability of system to be &quot;easy-2&quot; or extremely easy-1&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Seizure Frequency</measure>
    <time_frame>Up to 24 Month visit</time_frame>
    <description>Seizure frequency was calculated at 3, 6, 12, 18 and 24 month follow-up visits based on seizure diary information and compared to baseline estimates. Response rate was computed and summarized for partial seizures (SPS, CPS and CPS with 2nd GTCs) and overall seizure types as the percentage of patients that achieved ≥50% seizure reduction per month from baseline by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Seizure Severity Based on Physician Reported Questionnaire (NHS3)</measure>
    <time_frame>up to 24 Months Visit</time_frame>
    <description>Investigators completed the National Hospital Seizure Severity Scale (NHS3) questionnaire at screening, at the end of the EMU stay (provided a seizure occurred during the EMU stay), and at follow‐up visits. Severity was evaluated by seizure type. The range of NHS3 scale is 1-27 with 1 being the least severe and 27 being the most severe.
Negative median value means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Seizures Severity, Intensity &amp; Post-Ictal Recovery Based on Patient Completed Seizure Severity Questionnaire (SSQ)</measure>
    <time_frame>Up to 24 Month visit</time_frame>
    <description>Clinical outcomes such as seizure severity, intensity and post-ictal duration were also assessed during the long-term follow-up visits (3, 6, 12, 18 and 24 months) with patient reported questionnaires (SSQ; Seizure Severity Questionnaire). The range for SSQ (all sub-scores) is 1-7 with 1 being the least severe and 7 being the most severe.
Mean SSQ scores at 3, 6, 12, 18 and 24 months were compared to baseline. A change from baseline is calculated as baseline minus follow-up visit score to correspond to the Minimally Important Change (MIC) criteria as defined in the Scoring Scheme for SSQ v2. Questionnaire. Subscale scores were averaged to compute the SSQ Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Seizures Ending During Stimulation by Type</measure>
    <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
    <description>Clinical outcomes including seizure duration and cessation were assessed with vEEG during EMU stay. Number of seizures treated with Automatic Stimulation during EMU were evaluated. Of these seizures, those ending during the 60 second course of Automatic Stimulation were assessed and tabulated by seizure type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Seizure Duration (Seconds) for All Seizure Types by Subgroup(ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</measure>
    <time_frame>Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay</time_frame>
    <description>Seizure duration was calculated using historical EEG data from patients enrolled in the trial and compared to the duration of seizures that occurred during the study EMU stay. The seizure start and end times were determined via clinical observation and/or through an adjudication process with qualified EEG reviewers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Post Ictal Duration (Seconds) for All Seizure Types (ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</measure>
    <time_frame>Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay</time_frame>
    <description>Post-ictal duration was quantified by identifying the time at which the number of EEG channels within the 95% confidence interval of relative power reaches a number that is consistent with that during the pre-seizure period. This measure represents the amount of time required following a seizure until the EEG recovers to the pre-seizure state. It is used to objectively estimate patient recovery time. Historical seizures were baseline EEG recordings measured during monitoring prior to implantation. Post-ictal duration is only reported for seizures with Post Ictal Duration (seconds) annotated and &gt;= 20% Heart Rate Rise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life on Patient Reported Questionnaire (QOLIE-31-P)</measure>
    <time_frame>up to 24 Months Visit</time_frame>
    <description>Quality of life data was collected using patient‐completed QOLIE‐31‐P surveys and compared between baseline and follow‐up visits. The MIC score for each subscale defines the threshold for Minimally Important Change. If a score exceeds the MIC Score, the improvement from baseline is considered clinically significant. The range for QOLIE-31-P (all sub-scores) is 0-100 with higher scores reflecting greater well-being.Subscale scores were averaged to compute the QOLIE Total Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Summary of Seizure Intensity by Subgroup</measure>
    <time_frame>Historical Seizures and Seizures during Epilepsy Monitoing Unit Stay</time_frame>
    <description>Quantitative evaluation of EEG was used to characterize the seizures that were treated with Automatic Stimulation. Intensity was evaluated by surveying the average power level from the 10-20 system EEG channel of maximum output during the course of the seizure. Intensity was only reported for seizures with intensity annotated and &gt;= 20% Heart Rate Rise. The relative intensity was calculated by normalizing the power calculations to the pre-seizure state, and thus the reported changes are dimensionless. n= number of seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stimulation Heart Rate Changes</measure>
    <time_frame>EMU stay</time_frame>
    <description>During a 1 hour period during the EMU stay, the VNS Therapy device was programmed to normal mode stimulation ON time 30 seconds, OFF time 5 minutes. AutoStim and Magnet Mode were programmed OFF. In this hour, 10 to 11 normal mode stimulations can be expected. Around each of these stimulations, ECG data were collected to assess potential stimulation related heart rate changes (during stimulation, after stimulation and after black-out time). A black-out time is a period after stimulation during which no seizure detections can occur, to ensure that potential stimulation related heart rate changes were not seen as ictal tachycardia that would trigger false positive detection. During the trial, the black-out time was programmed to 30 seconds. The heart rate changes for all stimulations and all patients were averaged.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Model 106 VNS Therapy System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model 106 VNS Therapy System</intervention_name>
    <description>The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.</description>
    <arm_group_label>Model 106 VNS Therapy System</arm_group_label>
    <other_name>AspireSR VNS Therapy System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinical diagnosis of medically refractory epilepsy dominated by
             partial seizures suitable for implantation with the Model 106 VNS Therapy System.

          -  Patients with a history of increased heart rate (tachycardia) associated with seizure
             onset based on clinical data obtained from medical history, admission/hospital charts,
             or prior neurophysiologic evaluations.

          -  Patients willing to undergo an EMU evaluation for a period of at least three days with
             activation of the AMM feature during that time.

          -  Patients having an average of ≥ 3 seizures per month based upon diary or patient
             reporting for the 3 months prior to the screening visit.

          -  Patients must have peak-peak R-wave amplitude greater than or equal to 0.40 mV on ECG
             measured from the proposed electrode location in the neck to the proposed generator
             location in the chest via surface ECG electrodes in 7 different body positions.

          -  Patients must be at least 18 years old.

          -  Patients must be in good general health and ambulatory.

          -  Patient must be willing and able to complete informed consent.

        Exclusion Criteria:

          -  Patients have had a bilateral or left cervical vagotomy.

          -  Patients currently use, or are expected to use, short-wave diathermy, microwave
             diathermy, or therapeutic ultrasound diathermy.

          -  A VNS Therapy System implant would (in the investigator's judgment) pose an
             unacceptable surgical or medical risk for the patient.

          -  Patients expected to require full body magnetic resonance imaging.

          -  Patients have a history of VNS Therapy.

          -  Patients have a documented history of clinically meaningful bradycardia (heart rate
             less than 50 bpm) associated with seizures.

          -  Patients with a significant psychiatric disorder, significant cognitive impairment,
             history of major depression, or suicidality as defined by DSM IV-TR that in the
             investigator's judgment would pose an unacceptable risk for the patient or prevent the
             patient's successful completion of the study.

          -  Patients with a history of status epilepticus within 3 months of study enrollment.

          -  Patients prescribed drugs specifically for a cardiac or autonomic disorder that in the
             investigator's opinion would affect heart rate response unless the patient has ictal
             tachycardia while taking said drugs. These include, but are not limited to, beta
             adrenergic antagonists (&quot;beta blockers&quot;).

          -  Patients with known clinically meaningful cardiovascular arrhythmias as well as
             patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
             Holter recording obtained at the screening visit.

          -  Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
             past 2 years.

          -  Patients with a history of only psychogenic or pseudo seizures.

          -  Women who are pregnant. Women of childbearing age must take a pregnancy test.

          -  Patients currently enrolled in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Olin</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Boon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Gent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epilepsie-Zentrum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universität</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kempenhaege</name>
      <address>
        <city>Heeze</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Boon P, Vonck K, van Rijckevorsel K, El Tahry R, Elger CE, Mullatti N, Schulze-Bonhage A, Wagner L, Diehl B, Hamer H, Reuber M, Kostov H, Legros B, Noachtar S, Weber YG, Coenen VA, Rooijakkers H, Schijns OE, Selway R, Van Roost D, Eggleston KS, Van Grunderbeek W, Jayewardene AK, McGuire RM. A prospective, multicenter study of cardiac-based seizure detection to activate vagus nerve stimulation. Seizure. 2015 Nov;32:52-61. doi: 10.1016/j.seizure.2015.08.011. Epub 2015 Sep 21.</citation>
    <PMID>26552564</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2016</results_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Automatic Magnet Mode (AMM)</keyword>
  <keyword>Vagal Nerve Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible subjects were at least 18 years old, with a clinical diagnosis of medically refractory epilepsy dominated by partial seizures suitable for implantation with the Model 106 VNS Therapy System and a history of ictal tachycardia, defined as heart rate above 100 bpm during a seizure and at least a 55% increase or 35 bpm increase from baseline.</recruitment_details>
      <pre_assignment_details>A total of 35 subjects were screened; (4) did not meet study criteria, (31) were treated/implanted with the AspireSR® VNS Therapy® System, of which (1) was implanted with version 1 of the AspireSR® VNS Therapy® System and (30) were implanted with version 2 (= ITT population).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enrolled and Treated Population (Safety Population)</title>
          <description>Consists of all patients who provided consent and were implanted with the AspireSR VNS Therapy System version 1 or version 2. The safety population will be used for all safety analyses. (N=31 subjects).
In version 2 of the AspireSR VNS Therapy System, the TVS diodes (present in version 1) were removed from the electrical circuit to address the accumulation of electrical charge on the sensing node (e.g. generator-can) following delivery of a stimulation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who provided consent and were implanted with the AspireSR VNS Therapy System version 1 or version 2.</population>
      <group_list>
        <group group_id="B1">
          <title>VNS Therapy (Safety Population)</title>
          <description>The safety population consists of all patients who provided consent and were implanted with the AspireSR VNS Therapy System version 1 or version 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="19" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 years or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cognitive Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Epilepsy Onset</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="2" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Epilepsy Onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Brain or Epilepsy Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Idiopathic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryptogenic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family History of Seizures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Seizures with Auras in the Past 2 Months</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Seizures Reported by Investigators and Triple Review</title>
        <description>Subjects were admitted to the EMU and underwent standard continuous data collection of vEEG and ECG for 3 to 5 days. If a seizure occurred during the EMU stay, clinical investigators annotated the start and stop times, the type of seizure, the presumed seizure onset location, and the lobe of origin as applicable.
Following the EMU data collection phase of the trial, the de-identified, continuous electronic records (per patient) from the EMU period were provided to an independent and blinded triple review panel. This panel evaluated the EEG data and annotated seizure onset, seizure offset, and a description of seizure type. In the absence of video, seizure types could only be specified as: partial (particular type not denoted), generalized (non-absence), absence, or partial with secondary generalization.</description>
        <time_frame>Epilepsy Monitoring Unit Stay</time_frame>
        <population>ITT Population: consists of all patients implanted with the AspireSR VNS Therapy System version 2 and who have any EMU record.</population>
        <group_list>
          <group group_id="O1">
            <title>Reported by Investigators</title>
            <description>All seizures that occurred during EMU stay and that were identified by investigators.</description>
          </group>
          <group group_id="O2">
            <title>Reported by Triple Review</title>
            <description>All seizures that occurred during EMU stay and that were identified by triple review post EMU.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Seizures from an ITT subject that were either identified by the investigator during EMU evaluation or during the triple review process of EEG data.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Seizures Reported by Investigators and Triple Review</title>
          <description>Subjects were admitted to the EMU and underwent standard continuous data collection of vEEG and ECG for 3 to 5 days. If a seizure occurred during the EMU stay, clinical investigators annotated the start and stop times, the type of seizure, the presumed seizure onset location, and the lobe of origin as applicable.
Following the EMU data collection phase of the trial, the de-identified, continuous electronic records (per patient) from the EMU period were provided to an independent and blinded triple review panel. This panel evaluated the EEG data and annotated seizure onset, seizure offset, and a description of seizure type. In the absence of video, seizure types could only be specified as: partial (particular type not denoted), generalized (non-absence), absence, or partial with secondary generalization.</description>
          <population>ITT Population: consists of all patients implanted with the AspireSR VNS Therapy System version 2 and who have any EMU record.</population>
          <units>Seizures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Seizure Types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Partial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simple Partial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial with Secondary Generalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Generalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sub-Clinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified Seizure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Sensitivity Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</title>
        <description>Sensitivity is the total number of seizures detected divided by the total number of seizures during EMU stay.Data used to support sensitivity analyses included digital ECG/EEG files,corresponding M106 device downloads,and CRF data.Seizure and non-seizure EEG segments were provided to independent reviewers to confirm seizure occurrence and define EEG seizure onset times.Seizure onset times were then compared with observed M106 device detections at the detection threshold setting for AutoStim that the patient was randomized to(SDA 2;60%,SDA 4;40%,SDA 6;20%).Sensitivity is only reported if the heart rate surpassed the programmed detection threshold.Number of participants is total number of subjects who had seizures during the EMU stay.
An &quot;Ictal tachycardia Seizure&quot; is a seizure with Ictal Heart rate &gt;= 100 bpm &amp; at least 55% increase, or 35 bpm increase from baseline) Bootstrap confidence intervals using 3000 bootstrap samples. n=total number of seizures; N= number of participants</description>
        <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
        <population>Patients from the ITT population who completed the EMU evaluation and that had at least one reported seizure during the EMU evaluation that was confirmed by triple review; (Investigator Reported Seizures + Triple Review).</population>
        <group_list>
          <group group_id="O1">
            <title>% Sensitivity</title>
            <description>Total number of seizures detected by M106 divided by the total number of seizures reported (investigator + confirmation by triple review) during the EMU stay</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Sensitivity Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</title>
          <description>Sensitivity is the total number of seizures detected divided by the total number of seizures during EMU stay.Data used to support sensitivity analyses included digital ECG/EEG files,corresponding M106 device downloads,and CRF data.Seizure and non-seizure EEG segments were provided to independent reviewers to confirm seizure occurrence and define EEG seizure onset times.Seizure onset times were then compared with observed M106 device detections at the detection threshold setting for AutoStim that the patient was randomized to(SDA 2;60%,SDA 4;40%,SDA 6;20%).Sensitivity is only reported if the heart rate surpassed the programmed detection threshold.Number of participants is total number of subjects who had seizures during the EMU stay.
An &quot;Ictal tachycardia Seizure&quot; is a seizure with Ictal Heart rate &gt;= 100 bpm &amp; at least 55% increase, or 35 bpm increase from baseline) Bootstrap confidence intervals using 3000 bootstrap samples. n=total number of seizures; N= number of participants</description>
          <population>Patients from the ITT population who completed the EMU evaluation and that had at least one reported seizure during the EMU evaluation that was confirmed by triple review; (Investigator Reported Seizures + Triple Review).</population>
          <units>percentage of True Positive Detections</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ictal Tachycardia Seizures, SDA 2 (n=1; N=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ictal Tachycardia Seizures, SDA 4 (n=8; N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ictal Tachycardia Seizures, SDA 6 (n=2; N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 70% heart rate increase, SDA 4 (n=3; N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60% heart rate increase, SDA 2 (n=1; N=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60% heart rate increase, SDA 4 (n=4; N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50% heart rate increase, SDA 4 (n=6; N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50% heart rate increase, SDA 6 (n=1; N=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40% heart rate increase, SDA 4 (n=9; N=2))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40% heart rate increase, SDA 6 (n=4; N=3))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30% heart rate increase, SDA 6 (n=8; N=4))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 20% heart rate increase, SDA 6 (n=12; N=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval not computable where the mean sensitivity equals to 100%, or where number of patients within the setting is less than or equal to 2 (acceleration cannot be calculated).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Modeled Sensitivity Based on Heart Rate Increase Associated With Seizures by SDA Setting Post-Processed Through Bench-top Device Simulant</title>
        <description>Sensitivity is defined as the total number of seizures detected divided by the total number of seizures during the EMU stay. Data used to support sensitivity analyses included digital ECG/EEG files, corresponding M106 device downloads, and CRF data. Seizure onset times were compared with modeled M106 device detections at the least sensitive setting capable of detecting the seizure based on the corresponding change in heart rate. The participants' surface ECG data collected during the trial and passed through DMSDAT, a validated bench‐top simulant of the Automatic Stimulation feature, was used to produce modeled results for each threshold for AutoStim setting (1;70%, 2;60%, 3;50%, 4;40%, 5;30% and 6;20%). Number of participants is total number of subjects who experienced seizures during the EMU stay.
Bootstrap confidence intervals using 3000 bootstrap samples.</description>
        <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
        <population>Patients from the ITT population who completed the EMU evaluation and that had at least one reported seizure during the EMU evaluation that was confirmed by triple review; (Investigator Reported Seizures + Triple Review).</population>
        <group_list>
          <group group_id="O1">
            <title>% Sensitivity</title>
            <description>Total number of seizures detected by M106 divided by the total number of seizures reported (investigator + confirmation by triple review) during the EMU stay</description>
          </group>
        </group_list>
        <measure>
          <title>Modeled Sensitivity Based on Heart Rate Increase Associated With Seizures by SDA Setting Post-Processed Through Bench-top Device Simulant</title>
          <description>Sensitivity is defined as the total number of seizures detected divided by the total number of seizures during the EMU stay. Data used to support sensitivity analyses included digital ECG/EEG files, corresponding M106 device downloads, and CRF data. Seizure onset times were compared with modeled M106 device detections at the least sensitive setting capable of detecting the seizure based on the corresponding change in heart rate. The participants' surface ECG data collected during the trial and passed through DMSDAT, a validated bench‐top simulant of the Automatic Stimulation feature, was used to produce modeled results for each threshold for AutoStim setting (1;70%, 2;60%, 3;50%, 4;40%, 5;30% and 6;20%). Number of participants is total number of subjects who experienced seizures during the EMU stay.
Bootstrap confidence intervals using 3000 bootstrap samples.</description>
          <population>Patients from the ITT population who completed the EMU evaluation and that had at least one reported seizure during the EMU evaluation that was confirmed by triple review; (Investigator Reported Seizures + Triple Review).</population>
          <units>percentage of True Positive Detections</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 70% heart rate increase at SDA 1 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100">Confidence interval left blank where the mean sensitivity equals to 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60% heart rate increase at SDA 2 (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="70" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50% heart rate increase at SDA 3 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="57.14" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40% heart rate increase at SDA 4 (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="73.68" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30% heart rate increase at SDA 5 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="76.67" upper_limit="97.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 20% heart rate increase at SDA 6 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="79.66" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Potential False Positives Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</title>
        <description>Potential false positive rate is defined as the sum across all patients of the total number of potential false positive detections divided by the sum across all patients of the appropriate monitoring time during the EMU stay. Data used to support the potential false positive rate analyses included digital ECG/EEG files retrieved from the EMU evaluation, corresponding M106 device downloads, and triple review results of EEG recordings.
The evaluated EMU monitoring time includes a daily 3 minutes stepping exercise during which patients stepped up and down on a step stool at a submaximal effort leve.</description>
        <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
        <population>ITT Population: all patients implanted with Model 106 VNS Therapy System Version 2 and who have any EMU record.
10 participants analyzed for &gt;=60% setting, 12 participants analyzed for &gt;=40% setting, 8 participants analyzed for &gt;=20% setting.</population>
        <group_list>
          <group group_id="O1">
            <title>Potential False Positives</title>
            <description>Potential False Positives Based on Heart Rate Increase Associated with Seizures by Randomized SDA Setting (AutoStim Per Hour)</description>
          </group>
        </group_list>
        <measure>
          <title>Potential False Positives Based on Heart Rate Increase Associated With Seizures by Randomized SDA Setting</title>
          <description>Potential false positive rate is defined as the sum across all patients of the total number of potential false positive detections divided by the sum across all patients of the appropriate monitoring time during the EMU stay. Data used to support the potential false positive rate analyses included digital ECG/EEG files retrieved from the EMU evaluation, corresponding M106 device downloads, and triple review results of EEG recordings.
The evaluated EMU monitoring time includes a daily 3 minutes stepping exercise during which patients stepped up and down on a step stool at a submaximal effort leve.</description>
          <population>ITT Population: all patients implanted with Model 106 VNS Therapy System Version 2 and who have any EMU record.
10 participants analyzed for &gt;=60% setting, 12 participants analyzed for &gt;=40% setting, 8 participants analyzed for &gt;=20% setting.</population>
          <units>Potential False Positive per Hour</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=60%, SDA 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.20" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40%, SDA 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.70" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20%, SDA 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="5.31" upper_limit="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Validation of Cardiac R-Wave Detection</title>
        <description>Cardiac R‐wave detection was evaluated against concurrent ECG data (i.e. detailed R‐wave test) collected during implant, the first titration visit, at the beginning of the EMU stay, and at the 12 month visit. R‐R intervals were calculated using detected R‐waves from the Implantable Pulse Generator (IPG) and from a standard ECG monitor during a pre‐specified time interval. A time series 10 seconds was recorded using the IPG SyncPulse feature. Simultaneously, a corresponding time series over the same interval was recorded using a standard ECG monitor. The total number of beats accurately detected in the entire study population is reported.</description>
        <time_frame>At Implant, First Titration Visit, Day 1 EMU and 12 Months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Beat Detection Sensitivity By Device IPG</title>
            <description>Cardiac R‐Wave Detection Sensitivity Based on Device IPG and ECG Monitor Comparison for 10 second Detection Window. &quot;n&quot; denotes the total number of patients with available R‐R wave data at the visit time point.</description>
          </group>
        </group_list>
        <measure>
          <title>Validation of Cardiac R-Wave Detection</title>
          <description>Cardiac R‐wave detection was evaluated against concurrent ECG data (i.e. detailed R‐wave test) collected during implant, the first titration visit, at the beginning of the EMU stay, and at the 12 month visit. R‐R intervals were calculated using detected R‐waves from the Implantable Pulse Generator (IPG) and from a standard ECG monitor during a pre‐specified time interval. A time series 10 seconds was recorded using the IPG SyncPulse feature. Simultaneously, a corresponding time series over the same interval was recorded using a standard ECG monitor. The total number of beats accurately detected in the entire study population is reported.</description>
          <population>ITT population</population>
          <units>percentage of beats accurately detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Implant (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Titration Visit (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EMU Day 1 (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Follow-up (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Latency Period: Analysis of Observed Latency for True Positive Detections by Randomized SDA Setting</title>
        <description>Latency is defined as the time difference between SDA detection time and the annotated seizure onset time. The earliest SDA detection was considered for each seizure. Seizure onset times were compared with M106 device detections at the randomized SDA setting. Negative latencies indicate that the SDA detection preceded the seizure onset time. The median latency is presented for seizures which met the definition of ictal tachycardia as well as all seizure types and indicate the observed latency range.</description>
        <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
        <population>ITT Population n=total number of seizures in each category</population>
        <group_list>
          <group group_id="O1">
            <title>Latency Analysis of Ictal Tachycardia Seizures</title>
            <description>The time difference between SDA detection of the ictal tachycardia seizure and the annotated seizure onset time.
Ictal Tachycardia Seizure is defined as a seizure with an increase from a baseline heart rate to a rate that is greater than 100 bpm and is at least a 55% increase or 35 bpm.</description>
          </group>
          <group group_id="O2">
            <title>Latency Analysis of All Seizure Types</title>
            <description>The time difference between SDA seizure detection time and the annotated seizure onset time (ALL seizures).</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Latency Period: Analysis of Observed Latency for True Positive Detections by Randomized SDA Setting</title>
          <description>Latency is defined as the time difference between SDA detection time and the annotated seizure onset time. The earliest SDA detection was considered for each seizure. Seizure onset times were compared with M106 device detections at the randomized SDA setting. Negative latencies indicate that the SDA detection preceded the seizure onset time. The median latency is presented for seizures which met the definition of ictal tachycardia as well as all seizure types and indicate the observed latency range.</description>
          <population>ITT Population n=total number of seizures in each category</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SDA 2 (n=1, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="19.5" lower_limit="-89" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDA 4 (n=6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="12" upper_limit="57"/>
                    <measurement group_id="O2" value="27.5" lower_limit="0" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDA 6 (n=2,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" lower_limit="-42" upper_limit="13"/>
                    <measurement group_id="O2" value="7" lower_limit="-112" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Factors and Usability of the AspireSR® VNS Therapy® System.</title>
        <description>Usability survey data were collected from all site personnel who used the handheld programmer to evaluate the usability of the AspireSR® VNS Therapy® System.The device usability survey contained 17 questions that measure usability on a five-point Likert scale ranging from &quot;Extremely Difficult&quot; (5) to &quot;Extremely Easy&quot; (1). Site personnel were asked to assess usability of the software features, instructions for use, training materials, and overall usability of the system at four different time points. The time points include implant/recovery and the end of EMU.
Usability was calculated as percentage of the users who found the usability of system to be &quot;easy-2&quot; or extremely easy-1&quot;.</description>
        <time_frame>At implant/recovery up to EMU Discharge (2 to 4 weeks)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Implant/Recovery</title>
            <description>Assessment of Device Usability at Implant and Recovery</description>
          </group>
          <group group_id="O2">
            <title>Day 5 EMU or EMU Discharge</title>
            <description>Assessment of Device Usability at EMU (Day 5 or Discharge)</description>
          </group>
        </group_list>
        <measure>
          <title>Human Factors and Usability of the AspireSR® VNS Therapy® System.</title>
          <description>Usability survey data were collected from all site personnel who used the handheld programmer to evaluate the usability of the AspireSR® VNS Therapy® System.The device usability survey contained 17 questions that measure usability on a five-point Likert scale ranging from &quot;Extremely Difficult&quot; (5) to &quot;Extremely Easy&quot; (1). Site personnel were asked to assess usability of the software features, instructions for use, training materials, and overall usability of the system at four different time points. The time points include implant/recovery and the end of EMU.
Usability was calculated as percentage of the users who found the usability of system to be &quot;easy-2&quot; or extremely easy-1&quot;.</description>
          <population>ITT Population</population>
          <units>Percentage of participants rated 1 or 2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Training Material (n=21, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's Manual (n=18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laminated Instruction Card (n=20, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interrogation (Short) (n=22, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interrogation (Long) (n=21, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Parameters (n=22, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heartbeat Sensitivity Configuration (n=20, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure Detection Configuration (n=21, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>System Diagnostic (n=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View Database (n=17, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View Seizure Detection Data (n=15, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Export Data (n=7, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generator Battery Status Indicators (n=20, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Handheld Battery Status Indicator (n=19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warning Messages (n=13, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Usability (n=20, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Seizure Frequency</title>
        <description>Seizure frequency was calculated at 3, 6, 12, 18 and 24 month follow-up visits based on seizure diary information and compared to baseline estimates. Response rate was computed and summarized for partial seizures (SPS, CPS and CPS with 2nd GTCs) and overall seizure types as the percentage of patients that achieved ≥50% seizure reduction per month from baseline by visit.</description>
        <time_frame>Up to 24 Month visit</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Seizure Responder Rate</title>
            <description>Summary of Responders (&gt;= 50% Seizure Counts Reduction per Month) by Visit (All seizure types)</description>
          </group>
          <group group_id="O2">
            <title>Partial Seizures</title>
            <description>Summary of Responders (&gt;= 50% Seizure Counts Reduction per Month) by Visit (Partial Seizures)
Partial seizures consist of simple partial, complex partial, complex partial with secondarily generalized seizures.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Seizure Frequency</title>
          <description>Seizure frequency was calculated at 3, 6, 12, 18 and 24 month follow-up visits based on seizure diary information and compared to baseline estimates. Response rate was computed and summarized for partial seizures (SPS, CPS and CPS with 2nd GTCs) and overall seizure types as the percentage of patients that achieved ≥50% seizure reduction per month from baseline by visit.</description>
          <population>ITT population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up 3 Month n=29,27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="10.30" upper_limit="43.54"/>
                    <measurement group_id="O2" value="25.9" lower_limit="11.11" upper_limit="46.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up 6 Month n=30,28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="7.71" upper_limit="38.57"/>
                    <measurement group_id="O2" value="25" lower_limit="10.69" upper_limit="44.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up 12 Month n=27,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="16.52" upper_limit="53.96"/>
                    <measurement group_id="O2" value="36.0" lower_limit="17.97" upper_limit="57.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up 18 Month n=26,24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="17.21" upper_limit="55.67"/>
                    <measurement group_id="O2" value="37.5" lower_limit="18.80" upper_limit="59.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up 24 Month n=27,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="16.52" upper_limit="53.96"/>
                    <measurement group_id="O2" value="36.0" lower_limit="17.97" upper_limit="57.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Seizure Severity Based on Physician Reported Questionnaire (NHS3)</title>
        <description>Investigators completed the National Hospital Seizure Severity Scale (NHS3) questionnaire at screening, at the end of the EMU stay (provided a seizure occurred during the EMU stay), and at follow‐up visits. Severity was evaluated by seizure type. The range of NHS3 scale is 1-27 with 1 being the least severe and 27 being the most severe.
Negative median value means improvement.</description>
        <time_frame>up to 24 Months Visit</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Simple Partial Seizures</title>
            <description>NHS3 Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O2">
            <title>Complex Partial Seizures (CPS)</title>
            <description>NHS3 Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O3">
            <title>CPS w/2nd GTC</title>
            <description>NHS3 Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O4">
            <title>Generalized Tonic Clonic Sz</title>
            <description>NHS3 Scores at Follow-Up Visits</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Seizure Severity Based on Physician Reported Questionnaire (NHS3)</title>
          <description>Investigators completed the National Hospital Seizure Severity Scale (NHS3) questionnaire at screening, at the end of the EMU stay (provided a seizure occurred during the EMU stay), and at follow‐up visits. Severity was evaluated by seizure type. The range of NHS3 scale is 1-27 with 1 being the least severe and 27 being the most severe.
Negative median value means improvement.</description>
          <population>ITT Population</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to EMU Discharge; n=11,19,5,3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-10.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-14.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="-4.00" lower_limit="-5.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 3 Months; n=12,20,6,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-6.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-8.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-10.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-6.50" lower_limit="-13.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 6 Months; n=9,20,5,3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="-1.33" lower_limit="-9.0" upper_limit="3.2"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-14.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-12.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Months; n=9,20,6,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-1.83" lower_limit="-8.0" upper_limit="3.2"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-10.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-8.00" lower_limit="-10.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 18 Months; n=7,20,7,3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="-1.50" lower_limit="-12.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-8.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-7.00" lower_limit="-10.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 24 Months; n=8,20,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-4.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="-2.00" lower_limit="-12.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="-2.00" lower_limit="-3.0" upper_limit="-1.0"/>
                    <measurement group_id="O4" value="-8.00" lower_limit="-10.0" upper_limit="-6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to EMU Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 3 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.156</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.906</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 18 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 24 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.906</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to EMU Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 3 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 6 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>s</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 18 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 24 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to EMU Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>s</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to 3 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to 6 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to 18 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline to 24 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to EMU Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to 3 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to 6 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to 18 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to 24 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Seizures Severity, Intensity &amp; Post-Ictal Recovery Based on Patient Completed Seizure Severity Questionnaire (SSQ)</title>
        <description>Clinical outcomes such as seizure severity, intensity and post-ictal duration were also assessed during the long-term follow-up visits (3, 6, 12, 18 and 24 months) with patient reported questionnaires (SSQ; Seizure Severity Questionnaire). The range for SSQ (all sub-scores) is 1-7 with 1 being the least severe and 7 being the most severe.
Mean SSQ scores at 3, 6, 12, 18 and 24 months were compared to baseline. A change from baseline is calculated as baseline minus follow-up visit score to correspond to the Minimally Important Change (MIC) criteria as defined in the Scoring Scheme for SSQ v2. Questionnaire. Subscale scores were averaged to compute the SSQ Total Score</description>
        <time_frame>Up to 24 Month visit</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>SSQ Scores at 3 Months</title>
            <description>Change From Baseline at Each Category</description>
          </group>
          <group group_id="O2">
            <title>SSQ Scores at 6 Months</title>
            <description>Change From Baseline at Each Category</description>
          </group>
          <group group_id="O3">
            <title>SSQ Scores at 12 Months</title>
            <description>Change From Baseline at Each Category</description>
          </group>
          <group group_id="O4">
            <title>SSQ Scores at 18 Months</title>
            <description>Change From Baseline at Each Category</description>
          </group>
          <group group_id="O5">
            <title>SSQ Scores at 24 Months</title>
            <description>Change From Baseline at Each Category</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Seizures Severity, Intensity &amp; Post-Ictal Recovery Based on Patient Completed Seizure Severity Questionnaire (SSQ)</title>
          <description>Clinical outcomes such as seizure severity, intensity and post-ictal duration were also assessed during the long-term follow-up visits (3, 6, 12, 18 and 24 months) with patient reported questionnaires (SSQ; Seizure Severity Questionnaire). The range for SSQ (all sub-scores) is 1-7 with 1 being the least severe and 7 being the most severe.
Mean SSQ scores at 3, 6, 12, 18 and 24 months were compared to baseline. A change from baseline is calculated as baseline minus follow-up visit score to correspond to the Minimally Important Change (MIC) criteria as defined in the Scoring Scheme for SSQ v2. Questionnaire. Subscale scores were averaged to compute the SSQ Total Score</description>
          <population>ITT Population</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SSQ Total Score n=24,27,26,23,20 MIC=0.48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.516" spread="1.688"/>
                    <measurement group_id="O2" value="0.728" spread="1.567"/>
                    <measurement group_id="O3" value="0.354" spread="1.640"/>
                    <measurement group_id="O4" value="0.341" spread="1.461"/>
                    <measurement group_id="O5" value="0.966" spread="1.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity During Seizure; n=26,28,27,25,22 MIC=0.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.115" spread="2.783"/>
                    <measurement group_id="O2" value="1.643" spread="2.714"/>
                    <measurement group_id="O3" value="0.907" spread="2.557"/>
                    <measurement group_id="O4" value="0.800" spread="2.441"/>
                    <measurement group_id="O5" value="1.818" spread="2.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Recovery; n=25,29,27,27,26 MIC=0.39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.627" spread="3.101"/>
                    <measurement group_id="O2" value="0.663" spread="2.125"/>
                    <measurement group_id="O3" value="0.481" spread="2.514"/>
                    <measurement group_id="O4" value="0.280" spread="2.913"/>
                    <measurement group_id="O5" value="0.218" spread="2.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Severity; n=27,30,29,28,27 MIC=0.48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.519" spread="3.022"/>
                    <measurement group_id="O2" value="0.589" spread="2.097"/>
                    <measurement group_id="O3" value="0.425" spread="2.486"/>
                    <measurement group_id="O4" value="0.131" spread="2.855"/>
                    <measurement group_id="O5" value="0.160" spread="2.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postictal Emotional Rec. n=26,29,28,27,26 MIC=0.42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.397" spread="3.281"/>
                    <measurement group_id="O2" value="0.805" spread="2.832"/>
                    <measurement group_id="O3" value="0.179" spread="3.093"/>
                    <measurement group_id="O4" value="-0.062" spread="3.480"/>
                    <measurement group_id="O5" value="0.359" spread="3.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postictal Physical Reco; n=27,30,28,28,27 MIC=0.34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" spread="3.375"/>
                    <measurement group_id="O2" value="0.567" spread="2.208"/>
                    <measurement group_id="O3" value="0.393" spread="3.012"/>
                    <measurement group_id="O4" value="0.476" spread="3.018"/>
                    <measurement group_id="O5" value="0.012" spread="3.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postictal Cognitive Rec.;n=28,30,29,28,27 MIC=0.48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.536" spread="3.467"/>
                    <measurement group_id="O2" value="0.578" spread="2.946"/>
                    <measurement group_id="O3" value="0.805" spread="2.814"/>
                    <measurement group_id="O4" value="0.274" spread="3.587"/>
                    <measurement group_id="O5" value="0.099" spread="3.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>SSQ Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1529</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Activity During Seizures Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0942</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Overall Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2831</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Overall Severity Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3639</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Postictal Emotional Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4470</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Postictal Physical Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1311</p_value>
            <method>s</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Postictal Cognitive Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3898</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SSQ Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0511</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity During Seizures Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1106</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall Severity Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1273</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Postictal Emotional Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1305</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Postictal Physical Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1123</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Postictal Cognitive Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2309</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SSQ Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3191</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Activity During Seizures Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0679</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2082</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall Severity Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1790</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Postictal Emotional Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6869</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Postictal Physical Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6094</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Postictal Cognitive Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1530</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>SSQ Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3339</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Activity During Seizures Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1473</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Overall Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5035</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Overall Severity Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6653</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Postictal Emotional Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8622</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Postictal Physical Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4456</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Postictal Cognitive Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6876</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>SSQ Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0328</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Activity During Seizures Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5928</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall Severity Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7179</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Postictal Emotional Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5014</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Postictal Physical Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9640</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Postictal Cognitive Recovery Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8537</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Seizures Ending During Stimulation by Type</title>
        <description>Clinical outcomes including seizure duration and cessation were assessed with vEEG during EMU stay. Number of seizures treated with Automatic Stimulation during EMU were evaluated. Of these seizures, those ending during the 60 second course of Automatic Stimulation were assessed and tabulated by seizure type.</description>
        <time_frame>Epilepsy Monitoring Unit (EMU) Stay</time_frame>
        <population>ITT Population; All Treated Seizures n=total number of seizures</population>
        <group_list>
          <group group_id="O1">
            <title>Proportion of Seizures Ending During Stimulation by Type</title>
            <description>EMU seizures that were treated with Automatic Stimulation and ended during the course of the stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Seizures Ending During Stimulation by Type</title>
          <description>Clinical outcomes including seizure duration and cessation were assessed with vEEG during EMU stay. Number of seizures treated with Automatic Stimulation during EMU were evaluated. Of these seizures, those ending during the 60 second course of Automatic Stimulation were assessed and tabulated by seizure type.</description>
          <population>ITT Population; All Treated Seizures n=total number of seizures</population>
          <units>Percentage of Seizures Ending</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Seizures (not otherwise specified) (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simple Partial Seizures (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial Seizures (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Generalized Seizures (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Seizures (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debilitating Seizures (CPS, SGS, GEN) (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown Type (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Seizure Duration (Seconds) for All Seizure Types by Subgroup(ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</title>
        <description>Seizure duration was calculated using historical EEG data from patients enrolled in the trial and compared to the duration of seizures that occurred during the study EMU stay. The seizure start and end times were determined via clinical observation and/or through an adjudication process with qualified EEG reviewers.</description>
        <time_frame>Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay</time_frame>
        <population>Patients from the ITT population who had at least one seizure during the EMU stay and who had at least one historical seizure recorded (and duration was annotated). n=total number of seizures</population>
        <group_list>
          <group group_id="O1">
            <title>Historical Seizures</title>
            <description>Pre-study EEG recordings</description>
          </group>
          <group group_id="O2">
            <title>Terminated Seizures</title>
            <description>Seizures which ended during Automatic Stimulation</description>
          </group>
          <group group_id="O3">
            <title>Unstimulated Seizures</title>
            <description>Unstimulated seizures with &gt;20% increase in heart rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Seizure Duration (Seconds) for All Seizure Types by Subgroup(ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</title>
          <description>Seizure duration was calculated using historical EEG data from patients enrolled in the trial and compared to the duration of seizures that occurred during the study EMU stay. The seizure start and end times were determined via clinical observation and/or through an adjudication process with qualified EEG reviewers.</description>
          <population>Patients from the ITT population who had at least one seizure during the EMU stay and who had at least one historical seizure recorded (and duration was annotated). n=total number of seizures</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simple Partial Seizures n=6,4,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="28.9"/>
                    <measurement group_id="O2" value="40.5" spread="32.1"/>
                    <measurement group_id="O3" value="NA">no seizures reported</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial Seizures n=60,6,7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.2" spread="461.5"/>
                    <measurement group_id="O2" value="26.8" spread="16.2"/>
                    <measurement group_id="O3" value="150.7" spread="153.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPS Secondary Generalized n=12,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.3" spread="49.3"/>
                    <measurement group_id="O2" value="NA">no seizures reported</measurement>
                    <measurement group_id="O3" value="NA">no seizures reported</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Seizures n=0,6,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no seizures reported</measurement>
                    <measurement group_id="O2" value="20.3" spread="10.4"/>
                    <measurement group_id="O3" value="NA">no seizures reported</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debilitating Seizures n=72,12,7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.1" spread="421.5"/>
                    <measurement group_id="O2" value="23.6" spread="13.4"/>
                    <measurement group_id="O3" value="150.7" spread="153.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Post Ictal Duration (Seconds) for All Seizure Types (ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</title>
        <description>Post-ictal duration was quantified by identifying the time at which the number of EEG channels within the 95% confidence interval of relative power reaches a number that is consistent with that during the pre-seizure period. This measure represents the amount of time required following a seizure until the EEG recovers to the pre-seizure state. It is used to objectively estimate patient recovery time. Historical seizures were baseline EEG recordings measured during monitoring prior to implantation. Post-ictal duration is only reported for seizures with Post Ictal Duration (seconds) annotated and &gt;= 20% Heart Rate Rise</description>
        <time_frame>Historical Seizures and Seizures during Epilepsy Monitoring Unit Stay</time_frame>
        <population>Patients from the ITT population who had at least one seizure during the EMU stay and who had at least one historical seizure recorded (and duration was annotated). n=total number of seizures</population>
        <group_list>
          <group group_id="O1">
            <title>Historical Seizures</title>
            <description>Pre-study EEG recordings</description>
          </group>
          <group group_id="O2">
            <title>Terminated Seizures</title>
            <description>Seizures which ended during Automatic Stimulation</description>
          </group>
          <group group_id="O3">
            <title>Unstimulated Seizures</title>
            <description>Unstimulated seizures with &gt;20% increase in heart rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Post Ictal Duration (Seconds) for All Seizure Types (ITT Population) (Only Seizures With Post Ictal Duration (Seconds) Annotated)</title>
          <description>Post-ictal duration was quantified by identifying the time at which the number of EEG channels within the 95% confidence interval of relative power reaches a number that is consistent with that during the pre-seizure period. This measure represents the amount of time required following a seizure until the EEG recovers to the pre-seizure state. It is used to objectively estimate patient recovery time. Historical seizures were baseline EEG recordings measured during monitoring prior to implantation. Post-ictal duration is only reported for seizures with Post Ictal Duration (seconds) annotated and &gt;= 20% Heart Rate Rise</description>
          <population>Patients from the ITT population who had at least one seizure during the EMU stay and who had at least one historical seizure recorded (and duration was annotated). n=total number of seizures</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simple Partial Seizures n=5,4,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.6" spread="349.9"/>
                    <measurement group_id="O2" value="102.8" spread="110.2"/>
                    <measurement group_id="O3" value="NA">No seizures recorded</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial Seizures n=59,6,7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="67.3"/>
                    <measurement group_id="O2" value="85.7" spread="81.7"/>
                    <measurement group_id="O3" value="66.6" spread="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPS Secondary Generalized n=5,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.2" spread="199.3"/>
                    <measurement group_id="O2" value="NA">No seizures recorded</measurement>
                    <measurement group_id="O3" value="NA">No seizures recorded</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Seizures n=0,1,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No pre-study seizures (historical seizures) provided</measurement>
                    <measurement group_id="O2" value="9.4" spread="0.0"/>
                    <measurement group_id="O3" value="NA">No seizures recorded</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debilitating Seizures n=64,7,7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" spread="100.2"/>
                    <measurement group_id="O2" value="74.8" spread="79.9"/>
                    <measurement group_id="O3" value="66.6" spread="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life on Patient Reported Questionnaire (QOLIE-31-P)</title>
        <description>Quality of life data was collected using patient‐completed QOLIE‐31‐P surveys and compared between baseline and follow‐up visits. The MIC score for each subscale defines the threshold for Minimally Important Change. If a score exceeds the MIC Score, the improvement from baseline is considered clinically significant. The range for QOLIE-31-P (all sub-scores) is 0-100 with higher scores reflecting greater well-being.Subscale scores were averaged to compute the QOLIE Total Score.</description>
        <time_frame>up to 24 Months Visit</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>QOLIE-31-P Scores at 3 Months</title>
            <description>QOLIE‐31‐P Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O2">
            <title>QOLIE-31-P Scores at 6 Months</title>
            <description>QOLIE‐31‐P Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O3">
            <title>QOLIE-31-P Scores at 12 Months</title>
            <description>QOLIE‐31‐P Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O4">
            <title>QOLIE-31-P Scores at 18 Months</title>
            <description>QOLIE‐31‐P Scores at Follow-Up Visits</description>
          </group>
          <group group_id="O5">
            <title>QOLIE-31-P Scores at 24 Months</title>
            <description>QOLIE‐31‐P Scores at Follow-Up Visits</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life on Patient Reported Questionnaire (QOLIE-31-P)</title>
          <description>Quality of life data was collected using patient‐completed QOLIE‐31‐P surveys and compared between baseline and follow‐up visits. The MIC score for each subscale defines the threshold for Minimally Important Change. If a score exceeds the MIC Score, the improvement from baseline is considered clinically significant. The range for QOLIE-31-P (all sub-scores) is 0-100 with higher scores reflecting greater well-being.Subscale scores were averaged to compute the QOLIE Total Score.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QOLIE Overall Total (MIC=5.19) n=28,29,28,28,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="16.6"/>
                    <measurement group_id="O2" value="4.4" spread="18.7"/>
                    <measurement group_id="O3" value="8.9" spread="18.4"/>
                    <measurement group_id="O4" value="10.2" spread="15.9"/>
                    <measurement group_id="O5" value="8.7" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/Fatigue (MIC=5.25) n=28,29,28,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="17.6"/>
                    <measurement group_id="O2" value="-2.3" spread="17.9"/>
                    <measurement group_id="O3" value="4.3" spread="23.9"/>
                    <measurement group_id="O4" value="4.9" spread="21.0"/>
                    <measurement group_id="O5" value="6.9" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Well Being (MIC=4.76) n=28,29,28,28,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="25.1"/>
                    <measurement group_id="O2" value="-1.9" spread="21.4"/>
                    <measurement group_id="O3" value="7.1" spread="23.9"/>
                    <measurement group_id="O4" value="9.2" spread="24.7"/>
                    <measurement group_id="O5" value="8.2" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (MIC=3.95) n=27,28,26,27,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="25.8"/>
                    <measurement group_id="O2" value="11.6" spread="26.3"/>
                    <measurement group_id="O3" value="20.1" spread="30.9"/>
                    <measurement group_id="O4" value="14.6" spread="18.6"/>
                    <measurement group_id="O5" value="10.2" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning (MIC=5.34) n=28,29,28,27,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="27.7"/>
                    <measurement group_id="O2" value="12.4" spread="37.7"/>
                    <measurement group_id="O3" value="8.4" spread="30.3"/>
                    <measurement group_id="O4" value="13.6" spread="30.4"/>
                    <measurement group_id="O5" value="9.6" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Effects (MIC=5.00) n=28,29,28,26,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="35.9"/>
                    <measurement group_id="O2" value="3.3" spread="27.5"/>
                    <measurement group_id="O3" value="0.9" spread="21.4"/>
                    <measurement group_id="O4" value="5.7" spread="31.1"/>
                    <measurement group_id="O5" value="1.1" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure Worry (MIC=7.42) n=28,29,28,28,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="26.6"/>
                    <measurement group_id="O2" value="2.1" spread="24.4"/>
                    <measurement group_id="O3" value="7.7" spread="27.9"/>
                    <measurement group_id="O4" value="8.1" spread="18.9"/>
                    <measurement group_id="O5" value="7.5" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Quality of Life (MIC=6.42)n=28,29,28,28,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="25.9"/>
                    <measurement group_id="O2" value="6.2" spread="25.4"/>
                    <measurement group_id="O3" value="14.9" spread="24.7"/>
                    <measurement group_id="O4" value="15.0" spread="23.1"/>
                    <measurement group_id="O5" value="16.0" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>QOLIE Overall Total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2079</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Energy/Fatigue Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6562</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Emotional well being Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9376</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Social Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Cognitive functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8532</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Medication Effects Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4954</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Seizure Worry Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1877</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Overall Quality of Life Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4189</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>QOLIE Overall Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2365</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Energy/Fatigue Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4138</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Emotional well being Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8701</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0527</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cognitive functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1353</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medication Effects Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6927</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Seizure Worry Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4964</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall Quality of Life Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0238</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>QOLIE Overall Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0139</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Energy/Fatigue Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2822</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Emotional well being Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1363</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cognitive functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1293</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medication Effects Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5252</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Seizure Worry Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0642</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall Quality of Life Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>QOLIE Overall Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Energy/Fatigue Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4464</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Emotional well being Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0511</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Social Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cognitive Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0296</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medication Effects Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3115</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Seizure Worry Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Overall Quality of Life Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>QOLIE Overall Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0683</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Energy/Fatigue Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2226</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Emotional well being Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0823</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Social Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1459</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Cognitive Functioning Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2610</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9119</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Seizure Worry Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0826</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall Quality of Life Final Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Signed Rank Test</method>
            <method_desc>Null hypothesis: change from the baseline is equal to zero. The alternative hypothesis: change from the baseline is not equal to zero.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Summary of Seizure Intensity by Subgroup</title>
        <description>Quantitative evaluation of EEG was used to characterize the seizures that were treated with Automatic Stimulation. Intensity was evaluated by surveying the average power level from the 10-20 system EEG channel of maximum output during the course of the seizure. Intensity was only reported for seizures with intensity annotated and &gt;= 20% Heart Rate Rise. The relative intensity was calculated by normalizing the power calculations to the pre-seizure state, and thus the reported changes are dimensionless. n= number of seizures</description>
        <time_frame>Historical Seizures and Seizures during Epilepsy Monitoing Unit Stay</time_frame>
        <population>Patients from the ITT population who had at least one seizure during EMU stay and who had at least one historical seizure recorded. n=total number of seizures</population>
        <group_list>
          <group group_id="O1">
            <title>Historical Seizures</title>
            <description>Pre-study EEG recordings</description>
          </group>
          <group group_id="O2">
            <title>All EMU Stimulated Seizures</title>
            <description>Stimulated Seizures with &gt;= 20% increase in heart rate</description>
          </group>
          <group group_id="O3">
            <title>Terminated Seizures</title>
            <description>Seizures which ended during Automatic Stimulation</description>
          </group>
          <group group_id="O4">
            <title>Unstimulated Seizures</title>
            <description>Unstimulated seizures with =&gt;20% increase in heart rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Summary of Seizure Intensity by Subgroup</title>
          <description>Quantitative evaluation of EEG was used to characterize the seizures that were treated with Automatic Stimulation. Intensity was evaluated by surveying the average power level from the 10-20 system EEG channel of maximum output during the course of the seizure. Intensity was only reported for seizures with intensity annotated and &gt;= 20% Heart Rate Rise. The relative intensity was calculated by normalizing the power calculations to the pre-seizure state, and thus the reported changes are dimensionless. n= number of seizures</description>
          <population>Patients from the ITT population who had at least one seizure during EMU stay and who had at least one historical seizure recorded. n=total number of seizures</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Simple Partial Seizures n=6, 8, 4, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="33.9"/>
                    <measurement group_id="O2" value="225.3" spread="427.1"/>
                    <measurement group_id="O3" value="406.6" spread="581.0"/>
                    <measurement group_id="O4" value="NA">no seizures recorded</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex Partial Seizures n=60, 9, 6, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.4" spread="519.2"/>
                    <measurement group_id="O2" value="989.4" spread="2307.0"/>
                    <measurement group_id="O3" value="59.5" spread="65.2"/>
                    <measurement group_id="O4" value="51.6" spread="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPS Secondary generalized n=10, 2, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.1" spread="654.7"/>
                    <measurement group_id="O2" value="611.4" spread="832.2"/>
                    <measurement group_id="O3" value="NA">no seizures recorded</measurement>
                    <measurement group_id="O4" value="NA">no seizures recorded</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debilitating Seizures n=70, 12, 7, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.2" spread="541.2"/>
                    <measurement group_id="O2" value="852.1" spread="2002.8"/>
                    <measurement group_id="O3" value="65.0" spread="61.3"/>
                    <measurement group_id="O4" value="51.6" spread="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-stimulation Heart Rate Changes</title>
        <description>During a 1 hour period during the EMU stay, the VNS Therapy device was programmed to normal mode stimulation ON time 30 seconds, OFF time 5 minutes. AutoStim and Magnet Mode were programmed OFF. In this hour, 10 to 11 normal mode stimulations can be expected. Around each of these stimulations, ECG data were collected to assess potential stimulation related heart rate changes (during stimulation, after stimulation and after black-out time). A black-out time is a period after stimulation during which no seizure detections can occur, to ensure that potential stimulation related heart rate changes were not seen as ictal tachycardia that would trigger false positive detection. During the trial, the black-out time was programmed to 30 seconds. The heart rate changes for all stimulations and all patients were averaged.</description>
        <time_frame>EMU stay</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Percentage Change in Heart Rate</title>
            <description>Average percentage change in heart rate from pre-stimulation period to heart rate during VNS Therapy Stimulation, following VNS Therapy Stimulation, and following the black-out period.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-stimulation Heart Rate Changes</title>
          <description>During a 1 hour period during the EMU stay, the VNS Therapy device was programmed to normal mode stimulation ON time 30 seconds, OFF time 5 minutes. AutoStim and Magnet Mode were programmed OFF. In this hour, 10 to 11 normal mode stimulations can be expected. Around each of these stimulations, ECG data were collected to assess potential stimulation related heart rate changes (during stimulation, after stimulation and after black-out time). A black-out time is a period after stimulation during which no seizure detections can occur, to ensure that potential stimulation related heart rate changes were not seen as ictal tachycardia that would trigger false positive detection. During the trial, the black-out time was programmed to 30 seconds. The heart rate changes for all stimulations and all patients were averaged.</description>
          <population>ITT population</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During Stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Black-Out time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to 24 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VNS Therapy - Safety Population</title>
          <description>All adverse events were collected from baseline up to the 24-month follow-up visit for all subjects treated/implanted with the AspireSR® VNS Therapy® system. All SAEs are reported in the SAE data table, whereas only the most common AEs (&gt; 5%) are reported in the AE data table.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Incision Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage Subcutaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical Device Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea Exertional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wim Van Grunderbeek, Clinical Operations Manager Cyberonics Europe</name_or_title>
      <organization>Cyberonics Europe BVBA</organization>
      <phone>+32 2 720 95 93 ext 312</phone>
      <email>wim.vangrunderbeek@cyberonics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

